Trop-2 Drug Conjugate May Trump Chemo in HR+, HER2- BRCA Trop-2 Drug Conjugate May Trump Chemo in HR+, HER2- BRCA
If approved, the ADC would join sacituzumab govitecan (Trodelvy, Gilead) as agents that target trophoblast cell-surface antigen-2 (Trop-2), which is universally expressed in breast cancer.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
More News: American Health | Breast Cancer | Cancer | Cancer & Oncology | Hematology | HER2 | Trump | USA Health